Nevertheless, to prevent either anti-VEGF or possible anti-YKL-40 resistance, it should be taken into account for a combined regimen with anti-VEGF and anti-YKL-40 therapies in cancer patients. This evidence concerns the gene CHI3L1 and cancer.